---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-24-003209"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:33:24.646758+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cadrenal stockholders approve reverse split, share increase, and equity plan amendment

## Summary
- Approved reverse stock split at Board's discretion (1:2 to 1:20 ratio).
- Authorized share increase from 75M to 125M shares of common stock.
- Equity plan amendment adds 2,000,000 shares (total 4,604,550) and modifies evergreen provision to 20% of outstanding plus warrant shares.
- Elected directors John Murphy and Robert Lisicki to Class II until 2027.
- Ratified WithumSmith+Brown as independent auditor for 2024 fiscal year.

## SEC filing metadata
- accession: 0001013762-24-003209
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000101376224003209/0001013762-24-003209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000101376224003209/ea0210326-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-24-003209
- JSON: https://secwatch.observer/filing/0001013762-24-003209.json
- Plain text: https://secwatch.observer/filing/0001013762-24-003209.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.